• 1.

    Perkovic V, et al.; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024; 391:109121. doi: 10.1056/NEJMoa2403347

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Colhoun HM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med 2024; 30:20582066. doi: 10.1038/s41591-024-03015-5

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    2023 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. US Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2023. https://usrds-adr.niddk.nih.gov/2023

    • PubMed
    • Search Google Scholar
    • Export Citation

Get With the FLOW!

Ben Catanese Ben Catanese, MD, is a nephrology fellow, and Matthew A. Sparks, MD, FASN, is an associate professor of medicine in the Division of Nephrology, Duke University School of Medicine in Durham, NC.

Search for other papers by Ben Catanese in
Current site
Google Scholar
PubMed
Close
and
Matthew A. Sparks Ben Catanese, MD, is a nephrology fellow, and Matthew A. Sparks, MD, FASN, is an associate professor of medicine in the Division of Nephrology, Duke University School of Medicine in Durham, NC.

Search for other papers by Matthew A. Sparks in
Current site
Google Scholar
PubMed
Close
Restricted access
Save